SCHEMBL5544462

SCHEMBL5544462

[O]c1cccc(CCCCc2ccccc2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IGF1R P08069 1/20 0.52
▸ ALOX15 P16050 1/20 0.52
▸ MAOA P21397 3/20 0.50
▸ FAAH O00519 1/20 0.48
▸ MGLL Q99685 1/20 0.48
▸ MAPT P10636 1/20 0.48
▸ RXFP1 Q9HBX9 1/20 0.48
▸ MAOB P27338 4/20 0.48
▸ GSK3A P49840 2/20 0.47
▸ GSK3B P49841 2/20 0.47
▸ SIGMAR1 Q99720 4/20 0.47
▸ HDAC3 O15379 1/20 0.47
▸ MAPK1 P28482 1/20 0.47
▸ ADRA1A P35348 1/20 0.47
▸ HDAC4 P56524 1/20 0.47
▸ SLC6A3 Q01959 1/20 0.47
▸ HDAC1 Q13547 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ HDAC7 Q8WUI4 1/20 0.47
▸ HDAC2 Q92769 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5542132 0.98 MAPT (0.52) IGF1RALOX15MAOAFAAHMGLL
SCHEMBL5537546 0.98 MAPT (0.52) IGF1RALOX15MAOAFAAHMGLL
SCHEMBL5542870 0.96 HTR2A (0.48) IGF1RALOX15MAOAFAAHMGLL
SCHEMBL5539551 0.91 MAOA (0.56) ALOX15MAOAMAOBSMN1; SMN2TDP1
SCHEMBL8790729 0.83 MGLL (0.40) IGF1RALOX15MAOAMGLLSLC6A3
SCHEMBL4276383 0.83 LPL (0.56) L3MBTL1TDP1
SCHEMBL9435711 0.82 LPL (0.57) —
SCHEMBL3031829 0.82 MGLL (0.39) IGF1RALOX15MGLLMAPTRXFP1
SCHEMBL985766 0.82 LPL (0.57) —
SCHEMBL6270970 0.82 LPL (0.57) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 — — EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 — — EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 — — US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 — — US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 IGF1R 459/4885ALOX15 2847/4885MAOA 2885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback